The groundbreaking discovery and development of T-1201, a novel targeting small molecule-drug conjugate (SN38), and T-1301, an innovative multi-targeted tyrosine kinase inhibitor (TKI), have been selected for an oral presentation at the prestigious 16th Annual World Cancer Congress (WCC-2024).
News
News
![](https://www.taivex.com/wp-content/uploads/2022/10/iStock-news.png)
![](https://www.taivex.com/wp-content/uploads/2022/10/橙圓元素.png)
Groundbreaking Cancer Treatments T-1201 and T-1301 to be Presented at WCC-2024
![](https://www.taivex.com/wp-content/uploads/2016/09/iStock-1209787511.jpg)
Groundbreaking Cancer Treatments T-1201 and T-1301 to be Presented at WCC-2024
![](https://www.taivex.com/wp-content/uploads/2022/10/pill-1.png)
![](https://www.taivex.com/wp-content/uploads/2022/10/pill-2-1.png)
![](https://www.taivex.com/wp-content/uploads/2022/10/pill-3.png)
![](https://www.taivex.com/wp-content/uploads/2022/10/pill-2.png)
![](https://www.taivex.com/wp-content/uploads/2022/10/pill-1-1.png)